跳至主要内容
临床试验/NL-OMON43061
NL-OMON43061已完成不适用

Towards optimal personalized diet and vitamin supplementation in patients with a neuroendocrine tumor. - DIVIT

niversitair Medisch Centrum Groningen0 个研究点目标入组 53 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
53

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • * Adult patients aged * 18 years
  • * NET-patients with serotonine producing or non-serotonin producing tumors, with gastro-intestinal, pancreatic, bronchopulmonary or unknown primary tumor site and with metastasized or irresectable disease.
  • * Ability to comprehend Dutch (both reading and writing).
  • * Written informed consent provided.
  • * Use of somatostatin analogue for > 6 months.

排除标准

  • * Estimated life expectancy less than 6 months.
  • * Patients who have a history of another primary malignancy, except for radical and adequately treated malignancies from which the patient has been disease free for * 1 year.
  • * Major abdominal surgery during study period.
  • * Patients already participated in the DIVIT-pilot study
  • * Known hypersensitivity of (components of) somatostatin analogue

研究者

相似试验